Filing Flows › Biomerica (BMRA) › Q1 FY27 › vs Q4 FY26
Biomerica (BMRA) Q1 FY27 vs Q4 FY26 (quarter over quarter)
Biomerica's revenue rose $390K (+45%) from $875K in Q4 FY26 to $1.3M in Q1 FY27. The biggest changes: Clinical Lab +$364K (+89%); Over-the-counter +$189K (+185%); Contract Manufacturing −$162K (-45%).
Biomerica, Q1 FY27: revenue $1.3M (-8% year over year), operating margin -97.0%, net loss $1.2M, operating cash flow −$802K. The chart draws each line against Q4 FY26, the increases inside each band.
Every line
| Line | Q1 FY27 | Q4 FY26 | Change | % |
|---|---|---|---|---|
| Clinical Lab | $775K | $411K | $364K | +89% |
| Over-the-counter | $291K | $102K | $189K | +185% |
| Contract Manufacturing | $197K | $359K | −$162K | -45% |
| Physician's Office | $2K | $3K | −$1K | -33% |
| Revenue | $1.3M | $875K | $390K | +45% |
| Net loss | $1.2M | $1.1M | $87K | +8% |
| Costs & expenses | $2.5M | $2.4M | $84K | +3% |
| Operating costs | $2.5M | $2.4M | $84K | +3% |
| Income tax | $6K | $6K | $0 | 0% |
| Cost of revenue | $1.2M | $946K | $216K | +23% |
| Research & development | $206K | $205K | $1K | +0.5% |
| Operating cash sources | $1.2M | $1.1M | $87K | +8% |
| Depreciation & amortization | $15K | $17K | −$2K | -12% |
| Share-based compensation | $134K | $91K | $43K | +47% |
| Working capital & other | $281K | $125K | $156K | +125% |
| Cash used in operations | $802K | $912K | −$110K | -12% |
| Net loss absorbed | $1.2M | $1.1M | $87K | +8% |
Questions
How much did Biomerica's revenue grow quarter over quarter in Q1 FY27?
Biomerica's revenue rose $390K (+45%) from $875K in Q4 FY26 to $1.3M in Q1 FY27.
What drove Biomerica's revenue change in Q1 FY27?
Clinical Lab +$364K (+89%); Over-the-counter +$189K (+185%); Contract Manufacturing −$162K (-45%).